Prioritization of therapeutic targets of inflammation using proteomics, bioinformatics, and in silico cell-cell interactomics

  1. Get@NRC: Prioritization of therapeutic targets of inflammation using proteomics, bioinformatics, and in silico cell-cell interactomics (Opens in a new window)
DOIResolve DOI:
AuthorSearch for: ; Search for:
Journal titleMethods in Molecular Biology
Pages345360; # of pages: 16
Subjectintercellular adhesion molecule 1; neutralizing antibody; vascular cell adhesion molecule 1; amino acid sequence; article; bioinformatics; cell activation; cell communication and cell contact; cell interaction; cell surface; computer program; endothelium cell; human; human cell; inflammation; leukocyte; liquid chromatography; mass spectrometry; priority journal; protein analysis; protein folding; protein protein interaction; protein secretion; proteomics; T lymphocyte activation
AbstractLeukocyte extravasation is a multistep process, involving the movement of leukocytes out of the circulatory system, through vascular endothelium and to the site of tissue damage or infection. Protein-protein interactions play key roles in the extravasation process and have been attractive therapeutic targets for inhibiting inflammation using blocking (or neutralizing) antibodies. These targets include protein-protein interactions between cytokines (or chemokines) and their receptors on leukocytes and between adhesions molecules involving leukocyte-endothelium contacts. A number of therapeutics against these targets are currently used in clinic for treatment of inflammatory disorders, however, they are associated with side-effects partly due to the off-target actions (i.e., nonspecific targets). There is a need for novel targets involved in the leukocyte extravasation process that are specific to leukocyte subsets or to individual inflammatory disorder, and are amenable for drug development (i.e., duggable). In this chapter, we describe a methodology to identify novel "druggable" targets involving protein-protein interactions between activated leukocytes and endothelial cells using a combination of proteomics, bioinformatics and in silico interactomics. The result is a prioritized list of protein-protein interactions in a network consisting of leukocyte-endothelial cell communication and contacts. These prioritized targets can be pursued for the development of therapeutics such as neutralizing antibodies and for their validation through preclinical testing. The method described here provides the workflow to identify and clinically target important cell-cell interactions that are specific/selective for particular inflammatory disorders and to improve currently available therapies. © 2013 Springer Science+Business Media, LLC.
Publication date
AffiliationNational Research Council Canada (NRC-CNRC); Human Health Therapeutics (HHT-TSH)
Peer reviewedYes
NPARC number21269818
Export citationExport as RIS
Report a correctionReport a correction
Record identifierb0a2f6de-18a9-400a-8ad4-b4c725b29ebe
Record created2013-12-13
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)